CT1812 is a first-in-class, orally-administered small molecule that targets the sigma-2 receptor complex on neuronal synapses, displacing beta amyloid oligomers from their binding sites on brain cells and clearing them in to the cerebrospinal fluid.
The study included patients with mild to moderate Alzheimer's disease on donepezil therapy (n= 1315) and compared once-daily oral doses of intepirdine 35mg to placebo over 24 weeks.
Before study initiation, NSE levels were similar for both groups. On Day 3 of the study, the NSE levels were 7.95 ± 2.86 ng/mL for the memantine group and 12.33 ± 7.09 ng/mL for the control group (P=0.05).
The researchers found that in cross-sectional analyses, participants with self-reported or objective moderate and poor hearing were more likely to have a dementia diagnosis than those with normal hearing, after adjustment for potential confounders.
Both FPG CV and HbA1c CV were significant predictors of AD after adjustment for sociodemographic factors, lifestyle behaviors, diabetes-related variables, FPG and HbA1c, drug-related variables, and comorbidities.
After multivariable adjustment - which included duration of chronic medical conditions - a modest statistically significant association was only seen for psychomotor speed and attention.
"We found direct relationships between the frequency of word puzzle use and the speed and accuracy of performance on nine cognitive tasks assessing a range of aspects of function including attention, reasoning, and memory," researcher Keith Wesnes, PhD.
The researchers found that in fully adjusted models, participants with mid and high MedDiet scores were less likely to have poor cognitive performance than those with low scores.
The researchers found an association between greater AD pathology and worse subjective sleep quality, more sleep problems, and daytime somnolence.
"Collectively, these findings seem to support quite consolidated epidemiological evidence indicating that regular cocoa flavanols intake possesses the potential to protect human cognition, particularly in aged populations," write the authors.
"PPIs were not associated with greater risk of dementia or of Alzheimer's disease, in contrast to recent reports. Study limitations include reliance on self-reported PPI use and lack of dispensing data," the authors write.
The data indicated continuous PPI use was tied to a reduced risk of cognitive function decline vs. never use (hazard ratio [HR] 0.78, 95% CI: 0.66-0.93; P=0.005).
Nelotanserin is a novel once-daily oral 5HT2A inverse agonist. The 5HT2A receptor has been associated with neuropsychiatric effects, including visual hallucinations.
The scientists did find a relationship between gene variants associated with having a high BMI and type 2 diabetes, but there was no such connection in terms of Alzheimer's.
Over a median of 6 years of follow-up, chronic use of low-dose aspirin was not associated with onset of dementia or cognitive impairment.
Researchers said the gene mutation - called BDNF Val66Met allele, or the Met allele - was pinpointed by following 1,023 people who were at risk of developing Alzheimer's disease.
Otsuka and Lundbeck announced top-line results from two Phase 3 trials of brexpiprazole for the treatment of agitation in patients with dementia of the Alzheimer's type.
Analysis found that a higher recent and cumulative intake of artificially-sweetened soft drinks correlated with increased risk of ischemic stroke, all-cause dementia, and Alzheimer's disease dementia.
Researchers found that nursing homes enrolled in the OASIS program had a 7.6% drop in antipsychotic prescriptions, compared with a 3.9% decline at the other nursing homes.
The analysis showed that over a median of 6 years, chronic use of low-dose aspirin was not associated with onset of dementia or cognitive impairment.
Overall, the researchers found no variation in tolerability or adherence to the 3 medications based on gender, race, education or age.
We examined whether mental and behavioral disorders in general or specific mental and behavioral disorder categories increase the risk of Alzheimer's disease.
The researchers found that higher baseline HOMA-IR and fasting insulin levels were independent predictors of poorer verbal fluency performance (P=0.0002 for both) and of a greater decline in verbal fluency over follow-up (P=0.004 for both).
Analysis found that the use of benzodiazepines was significantly associated with an increased risk of pneumonia (aHR 1.28, 95% CI: 1.07-1.54) but not for the similarly acting non-benzodiazepines (aHR 1.10, 95% CI: 0.84-1.44).
While the GHR tests may provide genetic risk information, they cannot determine a person's overall risk for developing a disease, as other factors beyond genetics (ie, environment, lifestyle) may also influence risk.